In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making. Presenters: Rodney Hunter, PharmD, BCOP Director of Clinical Services Memorial Hermann Texas Medical Center Clinical Pharmacy Specialist University of Texas Health Memorial Hermann Cancer Center Professor Texas Southern University College of Pharmacy and Health Sciences Clinical Adjunct Professor McGovern Medical School Houston, Texas Julia L. Ziegengeist, PharmD, BCOP Clinical Pharmacist Specialist, Breast Medical Oncology Levine Cancer, Atrium Health Charlotte, North Carolina Link to full program:https://bit.ly/46SPGlU Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related